<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease (PH-ILD)</h2>
<p dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease (PH-ILD) is a chronic, progressive disorder that develops as a complication of fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD (CTD-ILD), and hypersensitivity pneumonitis. Progressive pulmonary vascular remodeling and elevated pulmonary arterial pressure increase the burden on the heart and lungs, leading to worsening exercise capacity, respiratory failure, and poor prognosis.</p>
<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of ILD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Type-specific Diagnosed Prevalent Cases of ILD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Type-specific Diagnosed Prevalent Cases of PH-ILD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of PH-ILD</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Gender-specific Diagnosed Prevalent Cases of PH-ILD</p>
</li>
</ul>
<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Across the 7 Major Markets (7MM), the total diagnosed prevalent population of PH-ILD was estimated at approximately 182K cases in 2025.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The United States accounted for 45% of diagnosed prevalent cases, followed by EU4 and the UK (39%) and Japan (16%).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">PH-ILD cases are projected to increase owing to aging populations and the growing prevalence of fibrosing ILDs, including IPF and CTD-ILD.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Improved survival among ILD patients, increased disease awareness, advances in imaging technologies, and more sensitive diagnostic approaches are contributing to earlier recognition of pulmonary hypertension.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The increasing burden of autoimmune diseases and continued environmental exposures are expected to further expand the PH-ILD patient population across the 7MM.</p>
</li>
</ul>
<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease Market</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Within the 7 Major Markets (7MM), the United States captured the largest share of the PH-ILD market in 2025, accounting for approximately 73% of the total market.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The PH-ILD market size across the 7MM was estimated at approximately USD 3 billion in 2025.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The market is projected to grow at a CAGR of 3.9% during the forecast period (2026&ndash;2036).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The PH-ILD market continues to expand due to increasing disease recognition, improved diagnostic techniques, and a growing population of patients with interstitial lung diseases.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The approval of inhaled therapies such as TYVASO and YUTREPIA, together with the development of novel targeted therapies, is expected to improve functional outcomes and support continued market growth.</p>
</li>
</ul>
<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease Market Drivers</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Rising prevalence of interstitial lung diseases is expanding the PH-ILD patient population.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Improved awareness and earlier diagnosis are enabling timely treatment initiation.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Increasing adoption of targeted pulmonary hypertension therapies is supporting market growth.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Expanding research and development activities continue to strengthen the future therapeutic landscape.</p>
</li>
</ul>
<h2 dir="ltr">Pulmonary Hypertension-associated with Interstitial Lung Disease Market Barriers</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Overlapping clinical symptoms with underlying ILD frequently delay diagnosis and appropriate treatment.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The lack of validated noninvasive biomarkers continues to limit early detection and disease monitoring.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Limited approved therapeutic options highlight the need for diversified treatment approaches in PH-ILD.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Reimbursement challenges and premium pricing of novel therapies may restrict patient access and market expansion.</p>
</li>
</ul>
<h2 dir="ltr">Emerging Pulmonary Hypertension-associated with Interstitial Lung Disease Drugs</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Mosliciguat</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">H1614 (HB-1614)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Treprostinil Liposomal (L606)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Treprostinil Palmitil Inhalation Powder (TPIP)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">And others</p>
</li>
</ul>
<h2 dir="ltr">Key Pulmonary Hypertension-associated with Interstitial Lung Disease Companies</h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Liquidia Corporation</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">United Therapeutics Corporation</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Roivant Sciences</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pulmovant</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Halo Biosciences</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pharmosa BioPharm</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Insmed</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">And others.</p>
</li>
</ul>
<p data-start="0" data-end="596">&nbsp;</p>

PH-ILD Market

PH-ILD Market Infograhics

PH-ILD Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape